- Associated Press•13 days ago
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 43 cents. Losses, adjusted for non-recurring costs, came to 40 cents per share. The drug developer posted revenue ...
- The Wall Street Journal•last month
Pfizer won bankruptcy-court approval to buy the assets of Bind Therapeutics after an auction doubled Pfizer’s starting offer, for a final price of $40 million.
- The Wall Street Journal•2 months ago
Pfizer Inc. has agreed to buy the assets of Bind Therapeutics Inc., a biotechnology company working on developing cancer treatments, out of bankruptcy for $20 million subject to higher bids at auction....
BIND THERAPEUTICS (2BT.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
As of 2:09 AM EDT. Market open.
|Bid||0.85 x 538800|
|Ask||0.95 x 403100|
|Day's Range||0.85 - 0.85|
|52wk Range||0.27 - 4.71|
|1y Target Est||N/A|
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||220|
|Dividend & Yield||N/A (N/A)|